H-ara-C (r ¼ 0.93, P ¼ 0.007), and with ara-C sensitivities (r ¼ À0.88, P ¼ 0.012), measured by a growth inhibition assay ( Figure 1 , panels a and b). To determine whether the relationship between dCK transcripts and ara-C metabolism/ sensitivities identified in AML cell lines could be extended to clinical samples, dCK transcripts were measured by realtime PCR in 46 diagnostic leukemia cells obtained from DS and non-DS children with AML, which had previously been characterized for ara-C metabolism and sensitivities.
7 dCK transcript levels in the patient samples spanned a 100-fold range, and were significantly higher in DS AML cells compared to non-DS cells (median 5.5-fold, Po0.0001), confirming our previous results with semiquantitative PCR. 7, 8 dCK transcripts from both the DS and non-DS groups significantly correlated with in vitro ara-CTP generation (r ¼ 0.55, P ¼ 0.011) and ara-C sensitivities (r ¼ À0.69, Po0.0001) (Figure 1 , panels c and d). These results confirm an important relationship between dCK expression and ara-C metabolism/ sensitivities in AML.
The variable levels of dCK transcripts in the AML cell lines may reflect differences in transcriptional regulation of the dCK gene. To further assess this possibility, the dCK promoterreporter gene construct (pdCK-464/ þ 75) 5 or promoterless pGL3-Basic (10 mg; Promega) were transiently co-transfected with 1 mg of pRLSV40 (Promega) into 1 Â 10 7 leukemia cells by electroporation (K562, 155 V, 1000 mF; CMK, CTS and Dami, 250 V, 950 mF; CMS and CMY, 200 V, 950 mF) . Cells were harvested and lysed for luciferase assay 48 h after transfection. As shown in Figure 2 , there was a significant correlation between dCK transcript levels and dCK promoter activities (r ¼ 0.86, P ¼ 0.023), suggesting a direct relationship between dCK transcription and dCK expression in the AML cell lines.
Differences in dCK transcripts between the cell lines or among the AML specimens could conceivably reflect variable intracellular levels of critical transcription factors. As expected, there were comparable levels of Sp1 and USF2a proteins on Western blots; however, USF1 protein levels were variable in the AML cell lines (data not shown). Analogous results were obtained by real-time PCR quantitation of these transcription factors (primers available on request) for both cell lines and AML specimens. For both the cell lines and patient specimens, differences in USF1 transcripts closely paralleled the variations in dCK transcripts (Figure 3) . These results suggest an important causal role for USF1 in regulating dCK expression in AML.
In conclusion, our findings significantly extend our previous results of ara-C metabolism/sensitivity and transcriptional regulation of dCK in AML cell lines and pediatric AML samples. We demonstrate significant correlations between dCK transcripts measured by real-time PCR, and in vitro ara-CTP generation and ara-C sensitivities in both AML cell lines and clinical AML samples from DS and non-DS children. This confirms the important relationship between expression of dCK, the rate-limiting enzyme in the phosphorylation and activation of ara-C, and ara-C sensitivity in AML. Although USF1, USF2a and Sp1 proteins have all been suggested to be important for dCK promoter activity, only USF1 transcripts significantly correlated with dCK transcripts in both AML cell lines and patient specimens. These results suggest that the intracellular levels of USF1 are key factors responsible for the variable levels of dCK transcripts in AML.
In our previous studies, we found that dCK transcripts were significantly higher in blast cells from DS children with AML compared to non-DS children, thus providing a partial explanation for the significantly increased sensitivity of this group to ara-C-based therapy. 6 What is the basis for the 5.5-fold median differential dCK expression between DS and non-DS leukemia cells? There was no significant difference in USF1 transcript levels detected between DS and non-DS AML cells (2.5 vs 1.9 relative units, respectively; P ¼ 0.49); however, this may reflect the small sample size. It is also conceivable that there are other regulatory elements in either the upstream or downstream regions of the dCK promoter, which account for differences in dCK expression between DS and non-DS AML cells. T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive postthymic malignancy with a median survival of 7.5 months.
1-3
Conventional chemotherapies such as deoxycoformycin may offer transient responses, but their efficacy is limited, 1-6 and there is currently no approved standard treatment for T-PLL. Here, we report the first patient with T-PLL who was successfully treated with unrelated cord blood (UCB) transplantation as salvage therapy after conventional chemotherapies failed.
In December 2003, a 52-year-old male presented with dyspnea on effort and dry cough. Physical examination revealed massive splenomegaly, facial edema and scattered, purplish, papular skin lesions on his extremities. His blood test showed a white blood cell (WBC) count of 76 Â 10 9 /l with 86% of abnormal lymphocytes, a hemoglobin level of 12.5 g/dl and a platelet count of 80 Â 10 9 /l. The lymphocytes were of small to medium size and had a folded nuclear outline, a single nucleolus and a deep basophilic cytoplasm. Flow cytometric analysis of peripheral blood lymphocytes revealed a postthymic T-cell phenotype (CD2 þ , CD3 þ , CD4 þ , CD5 þ , CD7 þ , CD8 þ ) with no B cell or myeloid antigens. Cytogenetic analysis revealed normal karyotype. The serological study for human Tlymphotropic virus 1 was negative. Bone marrow aspirate and pleural effusion aspirate showed massive infiltration of T prolymphocytes. Using peripheral blood samples, Southern blot analysis revealed a rearranged band in the T-cell receptor (TCR)-b chain gene. The diagnosis of T-PLL was made. The patient was treated sequentially with two regimens of combination chemotherapy (FND, fludarabine, mitoxantrone, dexamethasone; CHOP, cyclophosphamide, adriamycin, vincristine, prednisolone), and 2 0 -deoxycoformycin (DCF, 4 mg/m 2 weekly for four doses); however, these treatments did not result in complete remission. Since the disease could not be controlled by these treatments and was rapidly progressing, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was suggested. Since he had no human leukocyte antigen (HLA)-identical siblings and since coordinating an unrelated bone marrow transplantation would take a large amount of time, we proposed to perform a UCB transplantation. We made preparation for UCB transplantation using an unrelated banked UCB unit from the Placental Blood Bank at Tokyo through the Japan Cord Blood Bank Network.
7 The patient's weight was 58 kg and we could find suitable UCB as shown in Table 1 . The patient and donor cord blood were serologically and genotypically mismatched, that is, one-antigen mismatched in the graft-vs-host direction and two- 
